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Abstract 27 
Hyperhomocysteinemia (hHcy) has been associated with an increased risk of cardiovascular disease 28 
and stroke. Essential hypertension (EH), a polygenic condition, has also been associated with 29 
increased risk of cardiovascular related disorders.   To investigate the role of the homocysteine (Hcy) 30 
metabolism pathway in hypertension we conducted a case-control association study of Hcy pathway 31 
gene variants in a cohort of Caucasian hypertensives and age- and sex-matched normotensives. We 32 
genotyped two polymorphisms in the methylenetetrahydrofolate reductase gene (MTHFR C677T 33 
and MTHFR A1298C), one polymorphism in the methionine synthase reductase gene (MTRR A66G) 34 
and one polymorphism in the methylenetetrahydrofolate dehydrogenase 1 gene (MTHFD1 G1958A) 35 
and assessed their association with hypertension using chi square analysis. We also performed a 36 
multifactor dimensionality reduction (MDR) analysis to investigate any potential epistatic 37 
interactions among the four polymorphisms and EH. None of the four polymorphisms were 38 
significantly associated with EH and although we found a moderate synergistic interaction between 39 
MTHFR A1298C and MTRR A66G, the association of the interaction model with EH was not 40 
statistically significant (p=0.2367). Our findings therefore suggest no individual or interactive 41 
association between four prominent Hcy pathway markers and EH. 42 
 43 
Keywords:  1)essential hypertension; 2)homocysteine;  3)MTHFR;  4)MTRR; 5)MTHFD1; 6)MDR 44 
45 
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Introduction 46 
Hypertension is defined as a sustained systolic blood pressure of greater than 140mmHg or a 47 
diastolic blood pressure of greater than 90mmHg, or both[1]. Ninety five percent of hypertensives 48 
suffer from essential hypertension (EH) with the remaining 5% exhibiting high blood pressure due to 49 
some underlying disorder such as Liddle’s syndrome, glucocorticoid-remediable aldosteronism or 50 
apparent mineralocorticoid excess syndrome [1]. Worldwide, about one billion people suffer from 51 
hypertension while in Australia at least 30% of men and 20% of women are hypertensive [2]. In 52 
addition to the direct costs of treating EH, it is also a risk factor for many cardiovascular diseases 53 
(CVD), with EH implicated in 7.5 million deaths annually from ischaemic heart disease and stroke [3]. 54 
Determining the risk factors for EH is therefore important for understanding both EH and CVD and 55 
may help to develop new treatment or prevention strategies. 56 
 57 
There are a number of environmental and clinical risk factors associated with EH including, but not 58 
limited to, dietary intake of sodium, alcohol intake, lack of exercise, poor diet, obesity, insulin 59 
resistant diabetes and hyperlipidemia. Although these factors explain a substantial proportion of 60 
hypertension susceptibility, it is estimated that up to 60% of the variation in hypertension risk is due 61 
to an individual’s genetic makeup [4]. Thus, many studies have investigated the genetic component 62 
of hypertension using the well-known animal model, the spontaneous hypertensive rat [5], or 63 
undertaking genetic association and linkage studies [6] in hypertensive case-control and family 64 
cohorts. Investigations into the genetic component of hypertension have mainly focussed on the 65 
renin-angiotensin-aldosterone (RAA) system because of its importance in regulating normal blood 66 
pressure [7]. Other genes, such as those involved in the central nervous system, vascular-endothelial 67 
system and metabolic system, have also been extensively studied [7].  68 
 69 
The homocysteine (Hcy) pathway has emerged as a strong candidate for EH and many studies have 70 
investigated genetic variation underlying hyperhomocysteinemia (hHcy). However, results have so 71 
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far been inconclusive, with some studies reporting a significant association [8-10] while others have 72 
reported no association [11, 12]. The third National Health and Nutrition Examination Survey 73 
(NHANES III) reported that people with the highest level of Hcy carried a 2 to 3 fold increase in 74 
hypertension prevalence than those with the lowest Hcy level [13]. It is thought that Hcy levels are 75 
mainly increased by environmental factors such as lack of folate, vitamin B12 and vitamin B6 in the 76 
diet [14]; however, alterations in the Hcy pathway have also been shown to lead to mild hHcy in 77 
humans [15]. The Hcy pathway involves the conversion of Hcy to methionine. Briefly, 78 
tetrahydrofolate, a folic acid derivative, is converted to 5,10-methylenetetrahydrofolate (5,10-79 
MTHF) by the enzyme methylenetetrahydrofolate dehydrogenase 1 (MTHFD1). 5,10-MTHF is 80 
converted to 5-methyltetrahydrofolate by methylenetetrahydrofolate reductase (MTHFR). 81 
Ultimately this substrate reacts with Hcy to form methionine and regenerates tetrahydrofolate. 82 
Methionine synthase (MTR), in the presence of cobalamin (vitamin B12), regulates this reaction. 83 
However over time, cobalamin which is a strong reductant becomes oxidised, thereby inactivating 84 
the MTR enzyme. The enzyme methionine synthase reductase (MTRR) reactivates MTR by reducing 85 
cobalamin to its original state[16]. A simplified pathway is shown in Figure 1. 86 
 87 
One of the most studied genetic variants contributing to hHcy is the C to T single nucleotide 88 
polymorphism (SNP) at codon 677 of the MTHFR gene. The C to T substitution causes alanine to be 89 
substituted by valine. The TT variant codes for a thermolabile enzyme which has a 50% reduced 90 
activity compared to the CC variant [17]. Another SNP in the same gene occurs at codon 1298 with 91 
an A to C substitution. This leads to glutamine being substituted by alanine. Although the CC variant 92 
also reduces enzymatic activity, with its effect not as drastic as the TT variant occurring at codon 677 93 
[18], both polymorphisms result in a decrease in MTHFR enzyme activity, which decreases 94 
production of 5-methyltetrahydrofolate, the necessary substrate for Hcy conversion to methionine. 95 
By decreasing levels of 5-methyltetrahydrofolate, these polymorphisms could therefore result in 96 
accumulation of Hcy, leading to hHcy [15]. 97 
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Although the MTRR enzyme does not directly participate in the conversion of Hcy to methionine, the 98 
fact that it keeps the MTR enzyme active makes it a key enzyme in Hcy metabolism. A common SNP 99 
in MTRR is the A to G substitution at codon 66. This substitution causes isoleucine to be substituted 100 
by methionine in the enzyme. It has been reported that the mutant enzyme exhibits a four-fold 101 
lower activity in reactivating MTR than the wild type enzyme [19]. This polymorphism has also been 102 
associated with increased Hcy levels [20]. The MTHFD1 gene codes for a tri-functional enzyme: 5,10-103 
MTHF dehydrogenase, 5,10-MTHF cyclohydrolase and 10-formyltetrahydrofolate synthetase. The 104 
G1958A polymorphism results in the replacement of arginine by glycine within the synthetase active 105 
domain and reduces the enzymatic activity of MTHFD1 by about 26% [16], thereby disrupting 106 
methionine synthesis and possibly resulting in increased levels of Hcy. 107 
 108 
This study investigated whether there is an association between EH and the MTHFR C677T, MTHFR 109 
A1298C, MTRR A66G and MTHFD1 G1958A variants in an Australian case control cohort. An 110 
interaction analysis using the multifactor dimensionality reduction (MDR) method was also 111 
performed to investigate whether specific combinations of genotypes across all four loci contribute 112 
to disease status. 113 
 114 
MDR analysis is a data mining method used to detect and classify combinations of independent 115 
variables such as genotypes or environmental factors that may interact to cause disease. MDR 116 
classifies the genotype combinations of two loci (multi-locus genotype) into either belonging to a 117 
low-risk group or a high-risk group. For example, all possible genotypes at locus 1 (AA, Aa, aa) are 118 
paired with each other possible genotype at locus 2 (BB, Bb, bb), giving nine possible multi-locus 119 
genotypes (AA/BB, AA/Bb, AA/bb, and so on). Each multi-locus genotype is then evaluated for the 120 
number of cases versus controls, and assigned to be high-risk if the number of cases exceeds the 121 
number of controls, corresponding to a ratio > 1 for matched populations [21, 22]. If the ratio is < 1, 122 
the multi-locus genotype is defined as low-risk. When numbers are equal, multi-locus genotypes can 123 
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be assigned as affected (high-risk), unaffected (low-risk), or unassigned. This re-definition of two-124 
dimensional (two-locus) data as one dimension (risk value) is how MDR reduces the complexity of 125 
multi-dimensional data. The risk value dimension can then be analysed to predict the outcome 126 
variable (case or control status) using a non-parametric method which is better suited to deal with 127 
modelling of high-order interactions in small sample sizes. Non-parametric methods such as MDR 128 
are being increasingly used for genetic interaction analysis as they are model-free and are 129 
considered more robust than parametric methods [22]. 130 
 131 
Methods 132 
Study population 133 
The study protocol was approved by the Griffith University’s Ethics Committee. The study population 134 
was composed of 409 hypertensives and 409 age- (±5 years), sex- and ethnicity-matched 135 
normotensive controls, who resided in the South East Queensland region of Australia. All 136 
participants were of Caucasian origin. Cases were defined as individuals who were clinically 137 
diagnosed as suffering from hypertension and who were taking anti-hypertensive drugs. Controls 138 
were defined as participants who were not taking anti-hypertensive drugs, and whose blood 139 
pressure was less than 140/90 mmHg. Individuals suffering from renal disorders (polycystic kidneys, 140 
renovascular disease, parenchymal renal disease), primary aldosteronism, Cushing syndrome and 141 
hypothyroidism were excluded from the study. None of the participants included in the study 142 
reported any previous cardiovascular events such as heart attacks or stroke. 53.3% of the population 143 
was female and 46.7% was male. The average age of the case group was 63.1±10.9 years and the 144 
average age of the control group was 61.0±10.5 years. Peripheral blood samples as well as 145 
questionnaires detailing medical history, including blood pressure and prescribed medications, were 146 
obtained from all participants. All participants signed informed consent agreements prior to 147 
collection of blood and clinical information.  148 
 149 
7 
 
Genotyping methods 150 
DNA was extracted from blood samples using a modified version of the salting-out method[23]. Two 151 
polymorphisms in MTHFR and one polymorphism in MTRR and MTHFD1 were genotyped for all 152 
cases and controls. Detailed information regarding polymorphisms and a summary of assay 153 
conditions and primer sequences for each polymorphism are listed in Table 1. All PCR buffers, MgCl2, 154 
GoTaq polymerase were from Promega Corp., Madison, WI, USA; dNTPs, restriction enzymes, and 155 
enzyme buffers were from New England Biolabs, Ipswich, MA, USA; SYTO9 dye was from Invitrogen, 156 
Carlsbad, CA, USA. Protocol and assays for each polymorphism are described in detail below. 157 
 158 
MTHFR genotyping 159 
The MTHFR C677T polymorphism was genotyped by polymerase chain reaction (PCR) followed by 160 
restriction fragment length polymorphism (RFLP) analysis. The PCR protocol was as follows: 1X PCR 161 
buffer, 1.75mM MgCl2, 0.2mM dNTPs, 0.2uM forward primer, 0.2uM reverse primer, 1U GoTaq  and 162 
40ng of DNA. The primer sequences were designed by Frosst [24] and were validated as described in 163 
a previous study[25]. The PCR thermocycling conditions were as follows: 95oC for 3 mins, then 94oC 164 
for 40 seconds, 69oC for 40 seconds, and 72oC for 1 minute for 35 cycles, followed by a final 165 
extension step of 72oC for 5 minutes. The 198bp PCR products were electrophoresed on a 15cm 2% 166 
agarose gel containing 0.006% ethidium bromide) for 30 mins at 90V, and then visualised under 167 
ultraviolet light. 10ul of PCR product was then digested with 4U HinfI and 1X NEB Buffer 2 at 37oC for 168 
12hrs, followed by an 80oC enzyme deactivation step of 20 mins. Restriction digest products were 169 
electrophoresed on a 15cm 3.5% agarose gel for 120 min at 80V, which was then post-stained in a 170 
0.01% solution of ethidium bromide in 1X TAE buffer for 40 min and visualised under ultraviolet 171 
light. HinfI digestion of fragments containing the T allele produced two fragments of 175bp and 23bp 172 
while fragments containing the C allele remained undigested by HinfI.   173 
 174 
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The MTHFR A1298C polymorphism was genotyped by PCR followed by high resolution melt (HRM) 175 
analysis. The PCR protocol was as follows: 1X PCR buffer, 1.5mM MgCl2, 0.2mM dNTPs, 0.3uM 176 
forward primer, 0.3uM reverse primer, 1.6uM SYTO9, 1U GoTaq and 40ng of DNA. The primer 177 
sequences were obtained from a previous study [26] and were validated using an RFLP approach to 178 
genotype positive controls as described previously [27]. The PCR followed by high resolution melting 179 
analysis was conducted on a Qiagen Rotor-Q (Qiagen, Doncaster, VIC, Australia) and the 180 
thermocycling conditions were as follows: 95oC for 5 mins, then 95oC for 5 seconds and 60oC for 10 181 
seconds for 45 cycles. PCR products were melted from 78oC to 88oC at 0.1oC increments every 2 182 
seconds. Amplicon melting temperature (Tm) occurred at 83oC and three separate melt curves were 183 
obtained corresponding to the three genotypes AA, AC, and CC.  184 
 185 
MTRR genotyping 186 
The MTRR A66G polymorphism was genotyped by PCR followed by HRM analysis. The PCR protocol 187 
was as follows: 1X PCR buffer, 1.5mM MgCl2, 0.2mM dNTPs, 0.3uM forward primer, 0.3uM reverse 188 
primer, 1.6uM SYTO9, 1U GoTaq. The primer sequences were obtained from a previous study [28] 189 
and were validated using an RFLP approach described previously[27]. The PCR followed by HRM 190 
analysis was conducted on a Qiagen Rotor-Q and the thermocycling conditions were as follows: 95oC 191 
for 5 mins, then 95oC for 5 seconds and 60oC for 10 seconds for 45 cycles. PCR products were melted 192 
from 75oC to 85oC at 0.1oC increments every 2 seconds. Amplicon Tm occurred at 80oC and three 193 
separate melt curves were obtained corresponding to the three genotypes AA, AG, and GG.  194 
 195 
MTHFD1 genotyping 196 
The MTHFD1 G1958A polymorphism was genotyped by PCR followed by HRM analysis. The PCR 197 
protocol was as follows: 1X PCR buffer, 1.5mM MgCl2, 0.2mM dNTPs, 0.3uM forward primer, 0.3uM 198 
reverse primer, 1.6uM SYTO9, 1U GoTaq. The primer sequences were obtained from a previous 199 
study[29] and were validated using an RFLP approach to genotype positive controls as described 200 
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previously[29]. The PCR followed by HRM analysis was conducted on a Qiagen Rotor-Q and the 201 
thermocycling conditions were as follows: 95oC for 5 mins, then 95oC for 5 seconds and 60oC for 10 202 
seconds for 45 cycles. PCR products were melted from 79oC to 89oC at 0.1oC increments every 2 203 
seconds. Amplicon Tm occurred at 84oC and three separate melt curves were obtained 204 
corresponding to the three genotypes AA, AG, and GG.  205 
 206 
Statistical analysis 207 
Power analysis for this study was performed using the Power for Genetic Analyses software [30]. 208 
Genotype counts were tabulated for each of the four markers and genotype and allele frequencies 209 
were computed for each marker. All groups were tested for and found to be within Hardy-Weinberg 210 
equilibrium (HWE). Genotype and allele frequencies were compared between case and control 211 
groups for each marker using the chi square test, with two and one degrees of freedom respectively. 212 
All statistical analyses were performed using Microsoft Excel 2010 for Windows (v14.0). 213 
 214 
Interaction analysis 215 
Given the possibility that each variant may only contribute a small independent effect which may 216 
not be detectable as statistically significant in our case control cohort, we also performed interaction 217 
analysis using the MDR 2.0 software version beta 8.4. The MDR program was designed to test for 218 
interactive genetic effects on a trait even if the independent effects are non-significant [22].  219 
 220 
In the MDR software, main effect (one-locus) models, two-locus models, or N-locus models are 221 
generated, and each model is assessed for prediction accuracy by dividing the dataset into multiple 222 
sets, with one set excluded from model-training and then used to test the model. The process of 223 
division, model-training, and model-testing is repeated multiple times to cross-validate each model. 224 
Testing accuracy (TA) and cross-validation consistency (CVC) are then used to evaluate the overall 225 
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best model. Permutation testing can then be performed on the dataset using an additional module 226 
called MDRpt, which evaluates the significance of the model TA [22].   227 
 228 
Before performing the MDR analysis, all markers were examined for correlation using PLINK’s 229 
pairwise LD function [31], to identify SNPs that may be collinear. None of the four markers were 230 
found to be significantly correlated (r2 > 0.85) and all were used in the MDR analysis. Missing 231 
genotypes were then imputed by mode substitution. Software default settings were used except 232 
that the cross-validation was repeated 100 times, and paired analysis was selected. The model with 233 
the highest TA and CVC was determined to be the best model and significance p-values were then 234 
generated using 10,000 permutations in the MDR permutation testing module (MDRpt) version 1.0 235 
beta 2.  236 
 237 
Results 238 
This study has more than 90% power to detect a relative risk of at least 1.5 for all markers. Genotype 239 
and allele frequencies for all four markers are shown in Table 2. Of the 409 cases and 409 controls, 240 
377 cases (92.2%) and 393 controls (96.1%) and 368 cases (90.0%) and 386 controls (94.4%) were 241 
successfully genotyped for the MTHFR C677T and MTHFR A1298C markers respectively. For the 242 
MTRR A66G marker, 360 cases (88.0%) and 358 controls (87.5%) were successfully genotyped, and 243 
for the MTHFD1 marker, 364 cases (89.0%) and 360 controls (88.0%) were successfully genotyped. 244 
Samples which exhibited ambiguous melt curves for high resolution melt analysis were not counted 245 
resulting in a lower genotyping success rate compared to the RLFP assay. Both case and control 246 
groups across all four markers were found to be in HWE (p>0.05).  247 
 248 
For MTHFR, there was no statistically significant difference between the genotype frequencies of 249 
cases and controls for either the C677T marker (χ2=0.03, p=0.99) or the A1298C marker (χ2=1.10, 250 
p=0.58). There was also no statistically significant difference between the allele frequencies of cases 251 
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and controls for either the C677T (χ2=0.02, p=0.88) or the A1298C (χ2=0.16, p=0.69) polymorphisms. 252 
For the C677T marker, there was no observed trend in either the genotype or allele frequencies, 253 
with the TT genotype frequency at 8.7% for cases and 8.9% for controls, and the T allele frequency at 254 
31.8% for cases and 32.2% for controls. For the A1298C marker, there was an increased AA genotype 255 
frequency in cases (44.8%) compared to controls (42.0%), though this trend was less apparent in A 256 
allele frequency in cases (65.4%) compared to controls (64.4%). The observed minor allele 257 
frequencies in the control group for both the C677T marker (T allele, 32.2%) and the A1298C marker 258 
(C allele, 35.6%) conformed well with expected control frequencies for each marker (C677T, T allele, 259 
31%; A1298C, C allele, 36%) as determined in the Hap-Map CEU population (Utah residents of 260 
Northern European ancestry). 261 
 262 
Similarly, for the MTRR A66G polymorphism, there was no statistically significant difference between 263 
either the genotype frequencies of cases and controls (χ2=0.92, p=0.63), or the allelic frequencies of 264 
cases and controls (χ2=0.79, p=0.37). The GG genotype frequency was 18.1% for cases and 20.7% for 265 
controls, while allele frequencies showed a trend of decreased G allele frequency in cases (44.7%) 266 
compared to controls (47.1%). Although the genotype frequencies of our control group seemed 267 
markedly different to the Hap-Map CEU frequencies with 52.8% of heterozygotes in our control 268 
population compared to only 34.0% in the Hap-Map CEU population, the allelic frequencies of our 269 
control group (A allele, 52.9%) and the Hap-Map CEU population (A allele, 55.0%) were similar. 270 
 271 
For the MTHFD1 G1958A polymorphism, there was no statistically significant difference between 272 
cases and controls for either the genotype frequencies (χ2=1.73, p=0.42) or the allelic frequencies of 273 
cases and controls (χ2=0.31, p=0.58). The GG genotype frequency was 32.7% for cases and 28.9% for 274 
controls, while the G allele frequency was 55.8% for cases and 54.3% for controls The observed allele 275 
frequencies for our control group (G allele, 54.3%) was similar to expected allele frequencies as 276 
determined by the Hap-Map CEU population (G allele, 58.0%). Case and control genotype 277 
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frequencies were also analysed by gender (Table 3). There were 436 females (218 cases and 278 
controls) and 382 males (191 cases and controls); all groups were found to be in HWE. No significant 279 
differences between cases and controls were detected when analysed by gender and therefore all 280 
further analyses were performed using the entire population.  281 
 282 
For the MDR analysis, the best MDR models for the one SNP (main effect), two SNP, and three SNP 283 
combinations are shown in Table 4. The best model had a TA of 0.5526 and CVC of 100/100, and was 284 
a two-SNP model containing the MTHFR1298 and MTRR markers. Figure 2 shows the frequency of 285 
cases and controls for each multi-locus genotype in the model. The light grey cells indicate genotype 286 
combinations (MTHFR1298-MTRR) of the low risk group and the dark grey cells indicate genotype 287 
combinations of the high risk group. When multi-dimensional data under the MTHFR1298-MTRR 288 
model were collapsed into one dimension (risk level), the frequency of controls was higher in the 289 
low-risk group compared to cases (201 controls, 154 cases) while case frequency was higher in the 290 
high-risk group compared to controls (255 cases, 208 controls). There appears to be a moderate 291 
synergistic effect between MTHFR1298 and MTRR and a weaker synergistic effect between 292 
MTHFR677 and MTHFD1. However, the best model (MTHFR1298-MTRR model) was found not to be 293 
significantly associated with case status (p = 0.2367). 294 
 295 
Discussion 296 
We investigated the homocysteine pathway variants MTHFR C677T, MTHFR A1298C, MTRR A66G 297 
and MTHFD1 G1598A in an Australian Caucasian population for association with EH. There was no 298 
statistical difference between our case and control groups for either genotype or allele frequencies 299 
for any of the markers studied, indicating no detected association between these four markers and 300 
EH in our case-control population. However, given the sample size limitation, we could not rule out 301 
the possibility that these variants contributed a modest effect on EH in this cohort (OR<1.5) that was 302 
not detectable as statistically significant in this study, therefore, we conducted the interaction 303 
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analysis using an MDR approach. We found that the best model indicated an interaction between 304 
the two SNPs MTHFR A1298C and MTRR A66G, which was found to be non-significant by 305 
permutation testing. This may reflect the fact that the mechanism by which hHcy can cause 306 
hypertension is not well understood. However, a recent study in human umbilical artery smooth 307 
muscle cells reported an increase in the proliferation of vascular smooth muscle cells through the 308 
Hcy-mediated differential regulation of cyclin A and D1, which led to an increase in intima media 309 
thickness [32]. Another study on mesenteric arteries in mice showed that hHcy decreased 310 
bioavailability of nitric oxide by decreasing the expression of endothelial nitric oxide synthase 311 
through the activation of matrix metalloproteinases during oxidative stress [33]. These studies seem 312 
to implicate hHcy in vascular remodelling or vasoconstriction, suggesting a possible mechanism for 313 
EH development. 314 
 315 
MTHFR has been among the most studied genes in relation to Hcy and folate metabolism, with 316 
regard to a variety of diseases ranging from neural tube defects to CVD and EH. Previous studies 317 
have shown that the MTHFR variants C677T and A1298C have been associated with both higher 318 
levels of Hcy[15] and EH risk[34] directly. Currently, MTHFR C677T has been studied in relation to 319 
hypertension in 29 published papers indexed on the PubMed database, 25 of which were included in 320 
a meta-analysis conducted in 2007, which concluded that there was an overall association of MTHFR 321 
C677T with hypertension, with an OR of 1.343 (95%CI 1.198- 1.505) [35]. Overall, this is a less than a 322 
two fold increase in OR for EH cases, which may indicate that larger sample sizes would be needed 323 
to detect a modest effect. However, the sample size for this study (409 cases, 409 controls) is larger 324 
than the largest study included in the meta-analysis (247 cases, 249 controls). The meta-analysis also 325 
showed high heterogeneity between studies, with only 6 published studies showing a clear 326 
statistically significant association with EH, while 19 published studies had a non-significant OR [35]. 327 
However, studies included were from various countries and ethnicities, suggesting that population 328 
differences in allele frequency and association may have been confounded.  329 
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Another meta-analysis of Hcy metabolizing enzymes and risk of coronary heart disease consisting of 330 
23 studies reported an association of the C allele of the MTHFR A1298C with myocardial infarction 331 
with an OR of 1.37 (95% CI 1.03-1.84) [36]. However, conflicting results were obtained when the 332 
controls were subdivided and analysed with the C allele being associated with a decreased risk of 333 
coronary heart disease (CHD) in hospital-based case-control studies while it was associated with an 334 
increased risk of CHD in population-based case-control studies [36]. Overall, findings for MTHFR 335 
have therefore been varied and may represent differing MTHFR allele frequencies between ethnic 336 
groups, low power of small studies to detect modest effect sizes on CVD and EH risk, or a true lack of 337 
association between MTHFR variants and CVD and EH.  338 
 339 
 MTRR and MTHFD1 have both been shown to carry variants which decrease enzymatic activity and 340 
disrupt either MTR reactivation (for MTRR) or purine synthesis (for MTHFD1) though MTHFD1 has 341 
not been previously studied in relation to EH. The MTRR A66G polymorphism has been associated 342 
with increased Hcy levels [20]. However, a recent study of the MTRR A66G marker reported a lack of 343 
association with both Hcy concentration and risk of vascular disease [37], and a 2002 study in 344 
adolescents failed to find an association with EH [38]. This is the first study which has examined both 345 
MTRR and MTHFD1 in association with adult EH, and though individually they do not appear 346 
significantly associated with EH risk, it is possible that each variant confers only a modest effect. We 347 
hypothesised that an interaction analysis may have greater power to detect tiny effect sizes for each 348 
marker, and therefore conducted an interaction analysis using MDR. Though synergistic effects were 349 
detected, especially between MTHFR A1298C and MTRR, the best model was not found to be 350 
significant and therefore these effects may not be due to a true interaction between the variants, or 351 
may need to be confirmed in a larger case-control cohort. The interaction analysis did not detect 352 
MTHFR C677T as part of the best model, which is unexpected as the strongest individual association 353 
has been previously found between this variant and EH [35]; however, this may be because MTHFR 354 
C677T is not significantly associated with EH in this population. 355 
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Current data from this and other studies suggest that genes within the Hcy pathway are not 356 
significantly associated with an increase in EH risk, including the well-studied marker MTHFR C677T.  357 
Additionally, given that each gene may confer a modest effect to EH risk, a polygenic profile analysis 358 
of genes in the Hcy pathway may be warranted. Additionally, future studies should measure plasma 359 
Hcy levels to determine whether a combination of these markers influences Hcy levels overall. Our 360 
study could not verify whether Hcy levels are significantly different between our cases and controls, 361 
and whether individual markers or combinations of markers influence EH risk through elevating Hcy 362 
levels. Further, the effects of diet on Hcy levels and EH risk should be controlled for in any future 363 
analysis as protective diet such as high folate intake may abrogate an increased genetic risk to EH 364 
due to genetic variations in the Hcy pathway. 365 
366 
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Table 1: SNP and assay information 
Gene Location rs number SNP AA change Assay Primer sequence 
Product 
size Enzyme 
Digest 
Fragment 
MTHFR 1p36.3 rs1801133 C677T A222V PCR-RFLP FWD: 5’ TGAAGGAGAAGGTGTCTGCGGGA 3’ REV: 5’ AGGACGGTGCGGTGAGAGTG 3’ 198bp HinfI 
C - 198bp 
T – 175bp 
& 23bp 
MTHFR 1p36.3 rs1801131 A1298C E429A HRM FWD: 5’ CTTTGGGGAGCTGAAGGACTACTAC 3’ REV: 5’ CACTTTGTGACCATTCCGGTTTG 3’ 163bp N/A N/A 
MTRR 5p15.31 rs1801394 A66G I22M HRM FWD: 5’ GCAAAGGCCATCGCAGAAGACAT 3’ REV: 5’ AAACGGTAAAATCCACTGTAACGGC 3’ 118bp N/A N/A 
MTHFD1 14q24 rs2236225 G1958A R653Q HRM FWD: 5’ CATTCCAATGTCTGCTCCAA 3’ REV: 5’ GTTTCCACAGGGCACTCC 3’ 254bp N/A N/A 
AA = Amino acid; PCR-RFLP = Polymerase chain reaction - restriction fragment length polymorphism; HRM = High resolution melt 
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Table 2: Genotype and allele frequencies 
MARKER GENOTYPE FREQUENCIES ALLELE FREQUENCIES 
MTHFR C677T CC CT TT TOTAL C T TOTAL 
CASE 170 (45.1%) 174 (46.2%) 33 (8.7%) 377 514 (68.2%) 240 (31.8%) 754 
CONTROL 175 (44.5%) 183 (46.6%) 35 (8.9%) 393 533 (67.8%) 253 (32.2%) 786 
Test statistic χ2=0.03, p=0.99 (α=0.05) χ2=0.02, p=0.88 (α=0.05) 
MTHFR A1298C AA AC CC TOTAL A C TOTAL 
CASE 165 (44.8%) 151 (41.0%) 52 (14.2%) 368 481 (65.4%) 255 (34.6%) 736 
CONTROL 162 (42.0%) 173 (44.8%) 51 (13.2%) 386 497 (64.4%) 275 (35.6%) 772 
Test statistic χ2=1.10, p=0.58 (α=0.05) χ2=0.16, p=0.69 (α=0.05) 
MTRR A66G AA AG GG TOTAL A G TOTAL 
CASE 103 (28.6%) 192 (53.3%) 65 (18.1%) 360 398 (55.3%) 322 (44.7%) 720 
CONTROL 95 (26.5%) 189 (52.8%) 74 (20.7%) 358 379 (52.9%) 337 (47.1%) 716 
Test statistic χ2=0.92, p=0.63 (α=0.05) χ2=0.79, p=0.37 (α=0.05) 
MTHFD1 G1958A GG AG AA TOTAL G A TOTAL 
CASE 119 (32.7%) 168 (46.2%) 77 (21.1%) 364 406 (55.8%) 322 (44.2%) 728 
CONTROL 104 (28.9%) 183 (50.8%) 73 (20.3%) 360 391 (54.3%) 329 (45.7%) 720 
Test statistic χ2=1.73, p=0.42 (α=0.05) χ2=0.31, p=0.58 (α=0.05) 
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Table 3: Genotype and allele frequencies, analysed by gender 
MARKER GENOTYPE FREQUENCIES ALLELE FREQUENCIES 
MTHFR C677T CC CT TT TOTAL C T TOTAL 
MALE 
CASE 76 (46.1%) 75 (45.5%) 14 (8.5%) 165 227 (68.8%) 103 (31.2%) 330 
CONTROL 73 (39.9%) 93 (50.8%) 17 (9.3%) 183 239 (65.3%) 127 (34.7%) 366 
Test statistic χ2=1.35, p=0.51 (α=0.05) χ2=0.95, p=0.33 (α=0.05) 
FEMALE 
CASE 94 (44.3%) 99 (46.7%) 19 (9%) 212 287 (67.7%) 137 (32.3%) 424 
CONTROL 102 (48.6%) 90 (42.9%) 18 (8.6%) 210 294 (70%) 126 (30%) 420 
Test statistic χ2=0.77, p=0.68 (α=0.05) χ2=0.53, p=0.47 (α=0.05) 
MTHFR A1298C AA AC CC TOTAL A C TOTAL 
MALE 
CASE 77 (45.8%) 68 (40.5%) 23 (13.7%) 168 222 (66.1%) 114 (33.9%) 336 
CONTROL 86 (47.5%) 75 (41.4%) 20 (11%) 181 247 (68.2%) 115 (31.8%) 362 
Test statistic χ2=0.57, p=0.75 (α=0.05) χ2=0.37, p=0.54 (α=0.05) 
FEMALE 
CASE 88 (44%) 83 (41.5%) 29 (14.5%) 200 259 (64.8%) 141 (35.3%) 400 
CONTROL 76 (37.1%) 98 (47.8%) 31 (15.1%) 205 250 (61%) 160 (39%) 410 
Test statistic χ2=2.13, p=0.35 (α=0.05) χ2=1.24, p=0.27 (α=0.05) 
MTRR A66G AA AG GG TOTAL A G TOTAL 
MALE 
CASE 45 (28.1%) 81 (50.6%) 34 (21.3%) 160 171 (53.4%) 149 (46.6%) 320 
CONTROL 40 (24.2%) 92 (55.8%) 33 (20%) 165 172 (52.1%) 158 (47.9%) 330 
Test statistic χ2=0.93, p=0.63 (α=0.05) χ2=0.11, p=0.74 (α=0.05) 
FEMALE 
CASE 58 (29%) 111 (55.5%) 31 (15.5%) 200 227 (56.8%) 173 (43.3%) 400 
CONTROL 55 (28.5%) 97 (50.3%) 41 (21.2%) 193 207 (53.6%) 179 (46.4%) 386 
Test statistic χ2=2.29, p=0.32 (α=0.05) χ2=0.77, p=0.38 (α=0.05) 
MTHFD1 G1958A GG AG AA TOTAL G A TOTAL 
MALE 
CASE 59 (36.9%) 67 (41.9%) 34 (21.3%) 160 185 (57.8%) 135 (42.2%) 320 
CONTROL 48 (28.4%) 89 (52.7%) 32 (18.9%) 169 185 (54.7%) 153 (45.3%) 338 
Test statistic χ2=4.05, p=0.13 (α=0.05) χ2=0.63, p=0.43 (α=0.05) 
FEMALE 
CASE 60 (29.4%) 101 (49.5%) 43 (21.1%) 204 221 (54.2%) 187 (45.8%) 408 
CONTROL 56 (29.3%) 94 (49.2%) 41 (21.5%) 191 206 (53.9%) 176 (46.1%) 382 
Test statistic χ2=0.01, p=0.99 (α=0.05) χ2=0.00, p=0.95 (α=0.05) 
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Table 4: Best MDR Models 
Model Training Accuracy Testing Accuracy CV Consistency P-value 
MTHFR1298 0.5270 0.4951 97/100 0.9621 
MTHFR1298_MTRR 0.5575 0.5526 100/100 0.2367 
MTHFR677_MTHFR1298_MTRR 0.5681 0.4780 68/100 0.9863 
CV = Cross-validation 
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Figure 1: Simplified homocysteine pathway 
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Figure 2: Frequencies of cases and controls for the best MDR model (MTHFR1298-MTRR). 
Low-risk combined genotypes are indicated by light grey cells and high-risk combined genotypes are 
indicated by dark grey cells 
 
 
